0001628280-24-010531.txt : 20240312 0001628280-24-010531.hdr.sgml : 20240312 20240312160720 ACCESSION NUMBER: 0001628280-24-010531 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 17 CONFORMED PERIOD OF REPORT: 20240312 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240312 DATE AS OF CHANGE: 20240312 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Beauty Health Co CENTRAL INDEX KEY: 0001818093 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 851908962 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39565 FILM NUMBER: 24742120 BUSINESS ADDRESS: STREET 1: 2165 SPRING STREET CITY: LONG BEACH STATE: CA ZIP: 90806 BUSINESS PHONE: 800-603-4996 MAIL ADDRESS: STREET 1: 2165 SPRING STREET CITY: LONG BEACH STATE: CA ZIP: 90806 FORMER COMPANY: FORMER CONFORMED NAME: Vesper Healthcare Acquisition Corp. DATE OF NAME CHANGE: 20200714 8-K 1 skin-20240312.htm 8-K skin-20240312
FALSE0001818093Nasdaq00018180932024-03-122024-03-120001818093us-gaap:CommonStockMember2024-03-122024-03-12

 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549  
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): March 12, 2024
 
The Beauty Health Company
(Exact name of registrant as specified in its charter)  
 
Delaware 001-39565 85-1908962
(State or other jurisdiction
of incorporation)
 
(Commission
File Number)
 
(IRS Employer
Identification No.)
2165 Spring Street
Long Beach, CA
(Address of principal executive offices)

90806
(Zip Code)
(800) 603-4996
(Registrant’s telephone number, including area code)
Not Applicable
(Former name or former address, if changed since last report)
 
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐     Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class 
Trading
Symbol(s)
 
Name of each exchange
on which registered
Class A Common Stock, par value $0.0001 per share SKIN 
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company  ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐  
 


Item 7.01. Regulation FD Disclosure.

On March 12, 2024, The Beauty Health Company (the "Company") issued a press release announcing that the Company's Board of Directors (the "Board") has unanimously approved Marla Beck to be the Company's President and Chief Executive Officer, a copy of which is attached to this Current Report on Form 8-K ("Current Report") as Exhibit 99.1 and is incorporated herein by reference.

Ms. Beck has been the Interim Chief Executive Officer of the Company since November 20, 2023. Ms. Beck will also continue to serve on the Company's Board of Directors.

The Company intends to file a separate, subsequent Current Report on Form 8-K within four business days after the Company and Ms. Beck enter into a definitive employment agreement with respect to Ms. Beck becoming the Company's President and Chief Executive Officer.

The information set forth in Item 7.01 of this Current Report and Exhibit 99.1 contains forward-looking statements. These forward-looking statements are not guarantees of future performance and involve risks, uncertainties, and assumptions that are difficult to predict. Forward-looking statements are based upon assumptions as to future events that may not prove to be accurate. Actual outcomes and results may differ materially from what is expressed in these forward-looking statements.

The information set forth under Item 7.01 of this Current Report, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of such section. The information in Item 7.01 of this Current Report, including Exhibit 99.1, shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in any such filing, except as expressly set forth by specific reference in such a filing. This Current Report will not be deemed an admission as to the materiality of any information in this Current Report that is required to be disclosed solely by Regulation FD.

Item 8.01. Other Events.

The information provided in “Item 7.01 - Regulation FD Disclosure” of this Current Report is incorporated by reference into this Item 8.01.


Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description
104Cover Page Interactive Data File (embedded within the Inline XBRL document)


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Dated: March 12, 2024
The Beauty Health Company
By:/s/ Michael Monahan
Name:Michael Monahan
Title:Chief Financial Officer

 EX-99.1 2 ex991-marlaannouncementxfi.htm EX-99.1 Document


image_0.jpg

BeautyHealth Announces Appointment Of Marla Beck As
Chief Executive Officer

LONG BEACH, Calif., March 12, 2024 – The Beauty Health Company (NASDAQ: SKIN), home to flagship brand Hydrafacial, today announced its Board of Directors has unanimously approved Marla Beck as the Company’s permanent President and Chief Executive Officer. Ms. Beck has been Interim CEO since November 20, 2023, in addition to serving on the Company’s Board of Directors, which she will continue to do going forward.

“Over the past few months, the Board has undertaken an extensive search to identify BeautyHealth’s next CEO,” said Chairman of the Board Brent Saunders. “The Board unanimously agrees that Marla has done an outstanding job during her tenure as Interim CEO and that she is the right person to lead BeautyHealth into the future. Marla is an assured leader, focused on performance. As a beauty industry veteran, she brings a deep understanding of the sector and a track record of building enduring and authentic brands that deliver significant value. Marla possesses a deep understanding of the challenges and opportunities ahead for BeautyHealth, and the Board is confident in her steadying leadership.”
 
Before joining the BeautyHealth Board of Directors in June of 2022 and being appointed Interim Chief Executive Officer in November 2023, Ms. Beck established herself as a serial entrepreneur and visionary brand-builder. Ms. Beck is the founder and former CEO of Bluemercury, the disruptive omnichannel beauty and spa retailer founded in 1999.  She led Bluemercury from inception to a strategic sale to Macy’s in 2015 and continued to lead the company as an independent business unit of Macy’s until 2021. Under Ms. Beck’s leadership, Bluemercury’s presence spanned nearly 200 brick and mortar stores, a thriving e-Commerce platform, a highly penetrated loyalty program, and private label product brands M-61 Powerful Skincare and Lune+Aster Cosmetics.

Prior to founding Bluemercury, Ms. Beck was a consultant at McKinsey & Company. Ms. Beck holds a Bachelor of Arts degree from the University of California, Berkeley; an MBA from Harvard Business School; and an MPA from Harvard’s John F. Kennedy School of Government.

“It is an honor to step into the role of CEO of BeautyHealth,” said Ms. Beck. “The Company and our brands intrigue and inspire me, much like they do the entire beauty and aesthetics industry. As I have spent time in the day-to-day operations, I am more confident than ever in BeautyHealth’s growth potential and Hydrafacial’s particular competitive positioning with providers, partners and consumers. The Company’s intrinsic strengths are unmatched; and, along with a renewed focus on operational excellence and financial rigor, I am confident we will drive meaningful growth and value for employees, providers and shareholders.”




About The Beauty Health Company
The Beauty Health Company (NASDAQ: SKIN) is a global category-creating company delivering millions of skin health experiences every year that help consumers reinvent their relationship with their skin, bodies and self-confidence. Our brands are pioneers: Hydrafacial™ in hydradermabrasion, SkinStylus™ in microneedling, and Keravive™ in scalp health. Together, with our powerful global community of estheticians, partners and consumers, we are personalizing skin health for all ages, genders, skin tones, and skin types. We are committed to being ever more mindful in how we conduct our business to positively impact our communities and the planet. Find a local provider at https://hydrafacial.com/find-a-provider, and learn more at beautyhealth.com or LinkedIn.

Investors: IR@beautyhealth.com
Press: press@beautyhealth.com




 EX-101.SCH 3 skin-20240312.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.DEF 4 skin-20240312_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 5 skin-20240312_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Information [Line Items] Entity Information [Line Items] Document Period End Date Document Period End Date Equity Component [Domain] Equity Component [Domain] Class A Common Stock, par value $0.0001 per share Common Stock [Member] Pre-commencement Tender Offer Pre-commencement Tender Offer Soliciting Material Soliciting Material City Area Code City Area Code Entity Address, Postal Zip Code Entity Address, Postal Zip Code Entity Central Index Key Entity Central Index Key Equity Components [Axis] Equity Components [Axis] Entity Address, City or Town Entity Address, City or Town Security Exchange Name Security Exchange Name Title of 12(b) Security Title of 12(b) Security Written Communications Written Communications Local Phone Number Local Phone Number Trading Symbol Trading Symbol Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity Address, State or Province Entity Address, State or Province Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Cover [Abstract] Entity Emerging Growth Company Entity Emerging Growth Company Document Type Document Type Amendment Flag Amendment Flag Entity File Number Entity File Number Entities [Table] Entities [Table] Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Registrant Name Entity Registrant Name EX-101.PRE 6 skin-20240312_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT GRAPHIC 7 image_0.jpg begin 644 image_0.jpg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htm IDEA: XBRL DOCUMENT v3.24.0.1
Cover
Mar. 12, 2024
Entity Information [Line Items]  
Document Type 8-K
Document Period End Date Mar. 12, 2024
Entity Registrant Name The Beauty Health Company
Entity Incorporation, State or Country Code DE
Entity File Number 001-39565
Entity Tax Identification Number 85-1908962
Entity Address, Address Line One 2165 Spring Street
Entity Address, City or Town Long Beach
Entity Address, State or Province CA
Entity Address, Postal Zip Code 90806
City Area Code 800
Local Phone Number 603-4996
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Amendment Flag false
Entity Central Index Key 0001818093
Class A Common Stock, par value $0.0001 per share  
Entity Information [Line Items]  
Title of 12(b) Security Class A Common Stock, par value $0.0001 per share
Trading Symbol SKIN
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 14 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 2 22 1 false 1 0 false 0 false false R1.htm 0000001 - Document - Cover Sheet http://beautyhealth.com/role/Cover Cover Cover 1 false false All Reports Book All Reports skin-20240312.htm skin-20240312.xsd skin-20240312_def.xml skin-20240312_lab.xml skin-20240312_pre.xml http://xbrl.sec.gov/dei/2023 true false JSON 17 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "skin-20240312.htm": { "nsprefix": "skin", "nsuri": "http://beautyhealth.com/20240312", "dts": { "inline": { "local": [ "skin-20240312.htm" ] }, "schema": { "local": [ "skin-20240312.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "definitionLink": { "local": [ "skin-20240312_def.xml" ] }, "labelLink": { "local": [ "skin-20240312_lab.xml" ] }, "presentationLink": { "local": [ "skin-20240312_pre.xml" ] } }, "keyStandard": 22, "keyCustom": 0, "axisStandard": 1, "axisCustom": 0, "memberStandard": 1, "memberCustom": 0, "hidden": { "total": 3, "http://xbrl.sec.gov/dei/2023": 3 }, "contextCount": 2, "entityCount": 1, "segmentCount": 1, "elementCount": 28, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://beautyhealth.com/role/Cover", "longName": "0000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skin-20240312.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "skin-20240312.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "CommonStockMember", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Class\u00a0A Common Stock, par value $0.0001 per share", "label": "Common Stock [Member]" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntitiesTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitiesTable", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entities [Table]", "label": "Entities [Table]", "documentation": "Container to assemble all relevant information about each entity associated with the document instance" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInformationLineItems", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Information [Line Items]", "label": "Entity Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "EquityComponentDomain", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Component [Domain]", "label": "Equity Component [Domain]" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2023", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Equity Components [Axis]", "label": "Equity Components [Axis]" } } }, "auth_ref": [] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://beautyhealth.com/role/Cover" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 18 0001628280-24-010531-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-24-010531-xbrl.zip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skin-20240312_htm.xml IDEA: XBRL DOCUMENT 0001818093 2024-03-12 2024-03-12 0001818093 us-gaap:CommonStockMember 2024-03-12 2024-03-12 false 0001818093 NASDAQ 8-K 2024-03-12 The Beauty Health Company DE 001-39565 85-1908962 2165 Spring Street Long Beach CA 90806 800 603-4996 false false false false Class A Common Stock, par value $0.0001 per share SKIN NASDAQ false